Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Prostate Cancer |
Free Subscription
1 BJU Int |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Prostate Cancer is free of charge.
Efficacy of decision aid delivery modes in prostate cancer screening: umbrella
review and network meta-analysis.
BJU Int. 2024 Oct 14. doi: 10.1111/bju.16545.
PubMed
Abstract available
Investigation of association between clinically significant prostate cancer,
obesity and platelet to-lymphocyte ratio and neutrophil -to-lymphocyte ratio.
BMC Urol. 2024;24:226.
PubMed
Abstract available
Identification of a 5-gene signature panel for the prediction of prostate cancer
progression.
Br J Cancer. 2024 Oct 14. doi: 10.1038/s41416-024-02854.
PubMed
Abstract available
Metabolic, cardiac, and bone health testing in patients with prostate cancer on
androgen-deprivation therapy: A population-based assessment of adherence to
therapeutic monitoring guidelines.
Cancer. 2024 Oct 13. doi: 10.1002/cncr.35606.
PubMed
Abstract available
The LEAP2 Response to Cancer-Related Anorexia-Cachexia Syndrome in Male Mice and
Patients.
Endocrinology. 2024;165:bqae132.
PubMed
Abstract available
Androgen Deprivation Therapy in Intermediate Prostate Cancer Treated With
Radiation Therapy: The Wide Heterogeneity and Complexity of an Apparently Simple
Situation.
Int J Radiat Oncol Biol Phys. 2024;120:1008-1010.
PubMed
Late Urinary Toxicity After Extreme or Moderate Hypofractionated Prostate
Radiation Therapy in Patients With Prior Transurethral Resection of Prostate.
Int J Radiat Oncol Biol Phys. 2024;120:1011-1020.
PubMed
Abstract available
Editorial Comment to Loss of phosphatase and tensin homolog expression in
castration-sensitive prostate cancer predicts outcomes in men after
prostatectomy.
Int J Urol. 2024 Oct 15. doi: 10.1111/iju.15607.
PubMed
Can We Be Less Active in Prostate Cancer Surveillance?
J Urol. 2024 Oct 16:101097JU0000000000004277. doi: 10.1097/JU.0000000000004277.
PubMed
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
N Engl J Med. 2024;391:1413-1425.
PubMed
Abstract available
Racial disparities in prostate cancer in the UK and the USA: similarities,
differences and steps forwards.
Nat Rev Urol. 2024 Oct 18. doi: 10.1038/s41585-024-00948.
PubMed
Abstract available
IL-17RA/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer
growth.
Oncogene. 2024 Oct 18. doi: 10.1038/s41388-024-03169.
PubMed
Abstract available
The RECONCILE study protocol: Exploiting image-based risk stratification in early
prostate cancer to discriminate progressors from non-progressors (RECONCILE).
PLoS One. 2024;19:e0295994.
PubMed
Abstract available
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic
hormone-sensitive prostate cancer: A multicenter study.
Prostate. 2024 Oct 17:e24813. doi: 10.1002/pros.24813.
PubMed
Abstract available
Machine learning and explainable artificial intelligence to predict pathologic
stage in men with localized prostate cancer.
Prostate. 2024 Oct 13. doi: 10.1002/pros.24793.
PubMed
Abstract available
External Validation of a Previously Developed Deep Learning-based Prostate Lesion
Detection Algorithm on Paired External and In-House Biparametric MRI Scans.
Radiol Imaging Cancer. 2024;6:e240050.
PubMed
Abstract available
Preliminary efficacy, tolerability, and safety analysis of Darolutamide for
metastatic castration?resistant prostate cancer: a single-center, open-label
study.
Urol Int. 2024 Oct 15:1-13. doi: 10.1159/000541929.
PubMed
Abstract available
PSMA PET-targeted Biopsy for Prostate Cancer Diagnosis: Initial Experience from a
Multicenter Cohort.
Urology. 2024 Oct 17:S0090-4295(24)00909-9. doi: 10.1016/j.urology.2024.
PubMed
Abstract available
Should Military Veterans Be Classified as High Risk for Prostate Cancer
Screening? A Systematic Review and Meta-analysis.
Urology. 2024 Oct 17:S0090-4295(24)00908-7. doi: 10.1016/j.urology.2024.
PubMed
Abstract available
Thank you for your interest in scientific medicine.